# Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metas

Source: https://onco.cc/trials/nct05841472/  
OnCo record `nct05841472` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Camrelizumab, Pemetrexed, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by CrystalGenomics, Inc., now recruiting.

## Summary

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05841472 by CrystalGenomics, Inc., with 60 participants planned, started 2023-08-23 and due to reach its primary completion in 2026-08. Interventions recorded: Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin. Conditions listed: Non Squamous Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05841472
- Phase: 2
- Setting: An Open-label, Multi-center, Clinical Study to Evaluate Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Sponsor: CrystalGenomics, Inc.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT05841472: https://clinicaltrials.gov/study/NCT05841472

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)

---
JSON: https://onco.cc/api/v1/entities/nct05841472.json